基于指南决策支持系统改善中国基层高血压治疗的整群随机试验
该实用性整群随机试验纳入中国四地区94家基层机构,评估基于电子健康档案的临床决策支持系统(CDSS)对指南一致性降压治疗的影响。结果显示CDSS组指南一致性访视比例提高15.2个百分点,收缩压降幅多1.6 mm Hg,血压控制率改善未达统计学显著。
要点
- CDSS使指南一致性降压治疗访视比例从62.2%升至77.8%。
- CDSS组收缩压降幅较对照组多1.6 mm Hg,血压控制率差异未显著。
- 两组患者报告的治疗相关不良事件均少见。
核心结论
- 在中国基层使用CDSS可改善指南一致性降压治疗并提供适度血压降幅。
研究设计与样本
- 实用性、开放标签整群随机试验,纳入中国四地区94家基层机构,随机分配46家至CDSS、48家至常规照护。
主要发现
- 干预组收缩压降幅多1.6 mm Hg(95%CI -2.7至-0.5),P=0.006。
- 血压控制率(<140/90 mm Hg)干预组69.0%(3415/4952) vs 对照组64.6%(3778/5845),改善4.4个百分点(95%CI -0.7至9.5),P=0.07。
- 患者报告的治疗相关不良事件两组均少见。
关键数值与推荐
- CDSS推荐针对降压治疗起始、滴定或换药的指南一致性方案。
- 主要结局为高血压相关访视中提供适当(指南一致性)治疗的比例。
- 血压控制定义为<140/90 mm Hg。
临床怎么用
- 基层可考虑部署基于电子健康档案的CDSS以提升指南一致性降压治疗。
- CDSS带来的血压降幅适度,需结合其他管理策略综合评估。
局限性
- 血压控制率改善的95%CI跨越无效线且P=0.07,未达统计学显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the effectiveness of a clinical decision support system (CDSS) in improving the use of guideline accordant antihypertensive treatment in primary care settings in China. DESIGN: Pragmatic, open label, cluster randomised trial. SETTING: 94 primary care practices in four urban regions of China between August 2019 and July 2022: Luoyang (central China), Jining (east China), and Shenzhen (south China, including two regions). PARTICIPANTS: 94 practices were randomised (46 to CDSS, 48 to usual care). 12 137 participants with hypertension who used up to two classes of antihypertensives and had a systolic blood pressure <180 mm Hg and diastolic blood pressure <110 mm Hg were included. INTERVENTIONS: Primary care practices were randomised to use an electronic health record based CDSS, which recommended a specific guideline accordant regimen for initiation, titration, or switching of antihypertensive (the intervention), or to use the same electronic health record without CDSS and provide treatment as usual (control). MAIN OUTCOME MEASURES: The primary outcome was the proportion of hypertension related visits during which an appropriate (guideline accordant) treatment was provided. Secondary outcomes were the average reduction in systolic blood pressure and proportion of participants with controlled blood pressure (<140/90 mm Hg) at the last scheduled follow-up. Safety outcomes were patient reported antihypertensive treatment related events, including syncope, injurious fall, symptomatic hypotension or systolic blood pressure <90 mm Hg, and bradycardia. RESULTS: 5755 participants with 23 113 visits in the intervention group and 6382 participants with 27 868 visits in the control group were included. Mean age was 61 (standard deviation 13) years and 42.5% were women. During a median 11.6 months of follow-up, the proportion of visits at which appropriate treatment was given was higher in the intervention group than in the control group (77.8% (17 975/23 113) v 62.2% (17 328/27 868); absolute difference 15.2 percentage points (95% confidence interval (CI) 10.7 to 19.8); P<0.001; odds ratio 2.17 (95% CI 1.75 to 2.69); P<0.001). Compared with participants in the control group, those in the intervention group had a 1.6 mm Hg (95% CI -2.7 to -0.5) greater reduction in systolic blood pressure (-1.5 mm Hg v 0.3 mm Hg; P=0.006) and a 4.4 percentage point (95% CI -0.7 to 9.5) improvement in blood pressure control rate (69.0% (3415/4952) v 64.6% (3778/5845); P=0.07). Patient reported antihypertensive treatment related adverse effects were rare in both groups. CONCLUSIONS: Use of a CDSS in primary care in China improved the provision of guideline accordant antihypertensive treatment and led to a modest reduction in blood pressure. The CDSS offers a promising approach to delivering better care for hypertension, both safely and efficiently. TRIAL REGISTRATION: ClinicalTrials.gov NCT03636334.
引用
- Song J, Wang X, Wang B, et al. Learning implementation of a guideline based decision support system to improve hypertension treatment in primary care in China: pragmatic cluster randomised controlled trial. BMJ. 2024. PMID: 39043397. doi:10.1136/bmj-2023-079143
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。